Fluor Corporation plans to open new oligonucleotide therapeutics manufacturing facility. The new facility will be located in Colorado, USA.
The manufacturing facility laid at 275,000 square-foot will house two manufacturing lines to double manufacturing capability.
The new facility under construction will handle the synthesis, purification, and lyophilisation of custom nucleic acids (also known as oligonucleotides or oligos).
The new state-of-the-art engineering facility features advanced automation, water reduction strategies, and solvent capturing to optimise cost and construction. These improvements enable to fast-track the project and support global customers' needs by getting products to market faster.
The construction of the project is expected to be complete by 2026.